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M1 and 36.1%-46.6% of M2 received second line while 25.6%-32.3% of M1 and 18.2%-
25.1% of M2 received third line. Increasing the gap to 60 days decreased the total rate 
of second line therapy slightly for M1 patients to 43.0%-51.3% and to 33.0%-45.1% 
for M2. The rate of third-line therapy was similarly lower at 23.0%-30.0% for M1 
patients and 17.3%-23.2% for M2. Increasing from a 60-day to 90-day gap resulted 
in an absolute decline in the 60-day rate of therapy of 0.8%-2.6% in second line and 
0.3%-3.1% in third line across both the M1/M2 groups. CONCLUSIONS: The data are 
in agreement between the 2 databases, and analysis by varying treatment gaps did 
not significantly impact results.
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OBJECTIVES: Develop and validate an algorithm to define statin intolerance (SI) 
in an administrative database (AD). METHODS: Adults with ≥ 1 qualifying change 
in statin therapy and ≥ 1 prior diagnosis of hyperlipidemia, hypercholesterolemia, 
or mixed dyslipidemia were identified from the AD of the Health Alliance Plan 
at Henry Ford Health System (HFHS). A sample of 1000 patients was drawn from 
the pool of eligible adults using an 80/20 ratio of patients taking a moderate- to 
low-intensity statin or a high-intensity statin at the time of qualifying change in 
therapy. Statin utilization and adverse events data were abstracted from the AD 
and the HFHS electronic medical record (EMR). Patients were stratified by high 
or low cardiovascular risk based on comorbidities, and any SI was categorized as 
absolute (AI) or titration (TI). In both the AD and the EMR, identification of SI was 
based on statin treatment patterns and potential statin-related adverse events. 
With EMR as the reference, measures of concordance (Cohen’s kappa [κ ]) and 
accuracy (sensitivity, specificity, positive predictive value [PPV]) were reported for 
AD algorithms. RESULTS: In the sample population (n= 990), any SI was identified 
in 11.5% and 14.0%, AI in 2.2% and 3.1%, and TI in 9.7% and 11.8% of patients in the 
EMR and the AD, respectively. The algorithm identifying any SI had substantial 
concordance (κ= 0.66) and good sensitivity (78.1%), but modest PPV (64.0%). The 
TI algorithm performed better (κ = 0.74, sensitivity= 85.4%, PPV= 70.1%) than the 
AI algorithm (κ = 0.40, sensitivity= 50.0%, PPV= 35.5%). Specificity was high (> 94%) 
across all 3 algorithms. In the high cardiovascular risk cohort (n= 353), the any SI 
algorithm demonstrated robust concordance (κ = 0.73) and good sensitivity (80.9%) 
and PPV (75.3%), all of which were even higher for TI. CONCLUSIONS: A conserva-
tive but comprehensive, easily implementable, and valid SI algorithm from an AD 
is available for real-world research.
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OBJECTIVES: FDA-issued safety alerts and warnings play a vital role in post-mar-
ket drug surveillance. We examine the effects of the FDA safety announcements 
for rosiglitazone and pioglitazone on the utilization of these drugs and other oral 
antidiabetics. METHODS: We link safety announcements from the FDA MedWatch 
database to Medicare drug claims (Parts D & B) from 2006 to 2010. We examine the 
timing, direction and level of demand responses to safety announcements, and 
how they differ by patients’ race/ethnicity, socioeconomic status and plan type 
(PDP vs MA-PD). We then estimate the fraction of patients that continue using an 
“alerted” medication, switch to another oral antidiabetic, or stop use altogether 
(without adding another oral medication), and how these responses differ by patient 
group and plan type. RESULTS: The demand for rosiglitazone plummeted after the 
second safety alert (in May 2007), and decreased further after a (black box) warning 
was issued (in August). After the alert, 27% to 28% of rosiglitazone users switched 
to another oral antidiabetic (predominantly pioglitazone) within 6 months of the 
alert depending on patient groups and plan type; 28% to 33% discontinued use 
of rosiglitazone, but did not add another oral antidiabetic; 38% to 44% continued 
using rosiglitazone. After the warning, the numbers were 17% to 19%, 30% to 32% 
and 49% to 52% respectively. Discontinuation rates were slightly higher among 
Hispanics (32%) and those in MA-PD plans (32%). In contrast, the demand response 
for pioglitazone was more muted, while it increased slightly after the warning (in 
August). CONCLUSIONS: The demand response to safety warnings for rosiglita-
zone was large and abrupt, and a substantial fraction of those who stopped did not 
replace it with another oral antidiabetic. The demand response was fairly constant 
across race/ethnicity, socioeconomic status, and plan type, although large responses 
raise concern about adverse health consequences.
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OBJECTIVES: Breast cancer molecular subtypes provide important prognostic infor-
mation that is useful for determining adjuvant treatment strategies; however, there 
is no evidence to indicate molecular subtypes should influence choice of surgical 
treatment. The purpose of this study is to investigate the rates of mastectomy (TM) 
versus lumpectomy (BCT) for each T-stage subgroup based on hormone receptor sta-
tus. METHODS: The SEER registry was queried for all females ages 15 – 85 diagnosed 
with stage T1 or T2 invasive breast cancer from 2010-2011. Patients were stratified 
by T-stage and race. Logistic regression was used within each stratum to compare 
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OBJECTIVES: The measurement of healthcare is increasingly based on risk-adjusted 
outcomes derived from coded comorbidities in large datasets. However inaccurate or 
haphazard assessment of risk factors for morbidity and mortality in medical record 
codes can have tremendous implications for quality improvement and healthcare 
reform. The purpose of this study is to compare the prevalence of obesity, over-
weight, tobacco use and alcohol abuse of a large administrative dataset with a 
direct data collection survey. METHODS: We used the International Classification 
of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes for four lead-
ing comorbidities in the Nationwide Inpatient Sample (NIS) to compare them with 
a direct survey in the Behavioral Risk Factor Surveillance System (BRFSS) in 2011. 
The national and state estimates and the Pearson correlation coefficient for obe-
sity, overweight, smoking and alcohol abuse between NIS and direct survey were 
calculated. RESULTS: Compared with direct participant questioning in BRFSS, NIS 
reported substantially lower prevalence of obesity, overweight, smoking and alcohol. 
The prevalence of obesity, overweight, smoking and alcohol were 27.7%, 35.8%, 20.1% 
and 18.3% in direct survey and 9.6%, 0.21%, 12.2% and 4.6% in NIS. The correlation 
between NIS and direct survey was 0.27 for obesity (p= 0.06), 0.09 for overweight 
(p= 0.55), 0.62 for smoking (p< 0.01) and 0.40 for alcohol (p< 0.01). CONCLUSIONS: 
The prevalence of obesity, tobacco smoking and alcohol abuse based on ICD-9-CM 
codes in NIS is not consistent with prevalence rates by direct questioning. Patient-
level data extraction as a part of Meaningful Use standards, rather than ICD-9-CM 
codes, would improve the accuracy of these important contributors to patient out-
comes in NIS. Ensuring accuracy of important comorbidities is critical to quality 
improvement efforts and healthcare reform policies that are based on measuring 
risk-adjusted outcomes.
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OBJECTIVES: Hemophilia-related bleeding events are difficult to quantify. Insurance 
claims’ data may capture the information, but there is no robust methodology to 
identify these events. METHODS: Using 2004-2012 Truven Health MarketScan com-
mercial claims database (coverage of > 30 million employees in th United States), we 
evaluated males under age 65 having ≥ 1 inpatient/≥ 2 outpatient claims 30-day apart 
for hemophilia A or B (ICD-9: 286.0, 286.1), and ≥ 1 pharmacy claim for clotting factors 
VIII or IX with ≥ 12 months continuous enrollment from first hemophilia treatment 
were selected. Bleeding events were identified using ICD-9 codes for hemarthrosis, 
hematoma or other acute bleeds in inpatient/outpatient claims. Hemophilia treat-
ment guidelines recommend 1-14 day treatment depending on bleeding severity. 
We explored aggregating claims within varying time windows (1, 7, 10, and 14 days) 
to capture a single bleeding event and assessed sensitivity of the time differences 
using pairwise rank correlations. RESULTS: We identified 2,425 and 269 hemophilia 
A and B patients. Using a 7-day window, average annual bleeds ((total bleeds ÷ 
patient-months)*12) among patients with ≥ 1 bleed equaled 2.31 (range: 1-33) for 
hemophilia A and 1.92 (range: 1-18) for hemophilia B. Results were similar for a 
10-day window (hemophilia A: 2.21 (1-31), hemophilia B: 1.81 (1–14)) and 14-day 
window (hemophilia A: 2.10 (1–24), hemophilia B: 1.69 (1–12) ) ). A 1-day window 
produced somewhat higher numbers (hemophilia A: 2.99 (1-66), hemophilia B: 2.72 
(1-45)), but pairwise rank correlation remained high across the four assumptions 
(coefficients ≥ 0.99, p-values < 0.01 for both disease types). Frequencies are com-
parable to a large US-based study reporting bleeds in moderately-severe patients, 
albeit smaller than studies of severe patients. CONCLUSIONS: Claims data can 
be utilized to construct stable, robust indices of bleeding events in hemophilia 
patients, permitting reliable studies of factors influencing bleeding frequency and 
healthcare burden.
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OBJECTIVES: Compare changes in patterns of care and duration of therapy result-
ing from increasing the treatment gap designating a new line of therapy in meta-
static (M) gastric cancer (GaCa). METHODS: Two large integrated claims databases 
(Pharmetrics, MarketScan) spanning July 2008 to September 2012 were used to iden-
tify patients ≥ 18 years old diagnosed and treated for GaCa. Patients were required 
to be continuously enrolled for ≥ 6 months pre- and post-diagnosis. Eligible patients 
were stratified into cohorts based on the presence and timing of metastasis (M) 
diagnosis: no metastasis (NM), ≤ 120 days (M1), and ≥ 121 days (M2). Treatment gap 
intervals were varied at ≥ 30, ≥ 60 and ≥ 90 days to indicate the start of a new line of 
chemotherapy. RESULTS: There were 6,509 (3,486 NM; 1,469 M1; 654 M2) and 3,203 
(2,004 NM; 875 M1; 324 M2) patients in each of the databases meeting all inclu-
sion criteria. Comparing the 30- and 90-day gaps, mean length of treatment (days) 
increased for M1 patients from 69.8-71.0 to 83.4-84.5 in first, 55.4-56.6 to 55.7-60.3 
in second, and 56.5-59.7 to 60.1-64.9 in third line. Using a 30-day gap, 46.4%-54.2% of 
